|
Delayed
Cinnober Boat
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-.--% | - |
| 09-09 | BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating | MT |
| 09-08 | Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Pfizer Inc.(PFE)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Pfizer Inc.(PFE)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Pfizer Inc.(PFE)
EBIT
Dividend / Share (DPS)
Data source:
Pfizer Inc.(PFE)
Cash or Net Debt
- Stock Market
- Stocks
- PFE Stock
- PFZ Stock
- Consensus Pfizer
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
